Advances in Diabetes and Heart Disease From ESC 2022 Advances in Diabetes and Heart Disease From ESC 2022

The mortality risk of diabetes, the consistent efficacy of dapagliflozin, and adherence to SGLT2 inhibitors and GLP-1R agonists are some highlights from ESC 2022 chosen by Professor Pardeep Jhund.Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None ReCAP Source Type: news